Literature DB >> 3566182

Characterisation of gestodene binding to the oestrogen receptor in human malignant breast tissue.

M J Iqbal, A A Colletta.   

Abstract

Gestodene, a new synthetic progestogen, binds to progesterone receptor (PR) derived from normal breast, endometrium and both normal and diseased liver with an affinity 8-10 times higher than that of the natural ligand. PR in malignant breast could not be quantified on account of the binding of gestodene to oestrogen receptor (ER) in that tissue. Sucrose density ultracentrifugation using 3H-oestradiol and 3H-gestodene in normal and malignant breast demonstrated that the gestodene-ER complex in addition to exhibiting the 4S and 5S peaks showed an additional peak which sedimented at 2.9-3.15. Dissociation kinetics of gestodene from ER which was either heat-activated or molybdate-stabilised were comparable to the triphenylethylene class of antioestrogens in that the rate of dissociation, unlike that of oestradiol from ER, was unaffected by these treatments. The binding of ER-gestodene to DNA-cellulose was also investigated and was found to be approximately 30% less than that of ER-oestradiol.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3566182

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  1 in total

1.  The growth inhibition of human breast cancer cells by a novel synthetic progestin involves the induction of transforming growth factor beta.

Authors:  A A Colletta; L M Wakefield; F V Howell; D Danielpour; M Baum; M B Sporn
Journal:  J Clin Invest       Date:  1991-01       Impact factor: 14.808

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.